Cassava Sciences's (SAVA) Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

Go back to Cassava Sciences's (SAVA) Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

February 2, 2021 8:30 AM EST

- Patients Cognition Improved 1.6 Points on ADAS-Cog11 -- Patients Behavior Improved 1.3 Points on NPI -

- Improvements Maintained at 6 Months -

- Results Support Advancing Simufilam into Phase 3 Clinical Program -

AUSTIN, Texas, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimers disease. Patients... More